Target family: Calcitonin receptors (type: gpcr)
Target: CT receptor

Ligand: AC187 (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 7.150000095367432 pKB
Reference (Journal): Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes.
Published in: Mol Pharmacol

Ligand: adrenomedullin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Novel calcitonin-(8-32)-sensitive adrenomedullin receptors derived from co-expression of calcitonin receptor with receptor activity-modifying proteins.
Published in: Biochem Biophys Res Commun

Ligand: adrenomedullin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes.
Published in: Mol Pharmacol

Ligand: adrenomedullin 2/intermedin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.5 pEC50
Reference (Journal): Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes.
Published in: Mol Pharmacol

Ligand: α-CGRP (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Characterization of the human calcitonin gene-related peptide receptor subtypes associated with receptor activity-modifying proteins.
Published in: Mol Pharmacol

Ligand: α-CGRP (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes.
Published in: Mol Pharmacol

Ligand: α-CGRP (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Receptor-activity-modifying protein 1 forms heterodimers with two G-protein-coupled receptors to define ligand recognition.
Published in: Biochem J

Ligand: α-CGRP (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Coexistence of novel amylin-binding sites with calcitonin receptors in human breast carcinoma MCF-7 cells.
Published in: J Endocrinol

Ligand: amylin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Coexistence of novel amylin-binding sites with calcitonin receptors in human breast carcinoma MCF-7 cells.
Published in: J Endocrinol

Ligand: amylin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Coexistence of novel amylin-binding sites with calcitonin receptors in human breast carcinoma MCF-7 cells.
Published in: J Endocrinol

Ligand: amylin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or -3.
Published in: Endocrinology

Ligand: amylin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Pharmacological characterization of receptor-activity-modifying proteins (RAMPs) and the human calcitonin receptor.
Published in: J Pharmacol Toxicol Methods

Ligand: amylin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pEC50
Reference (Journal): Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes.
Published in: Mol Pharmacol

Ligand: amylin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pEC50
Reference (Journal): Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors.
Published in: Endocrinology

Ligand: β-CGRP (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.2 pEC50
Reference (Journal): Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes.
Published in: Mol Pharmacol

Ligand: calcitonin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1986)
Primary target: yes
Median affinity:  pEC50
Reference (Journal): Pharmacological characterization of receptor-activity-modifying proteins (RAMPs) and the human calcitonin receptor.
Published in: J Pharmacol Toxicol Methods

Ligand: calcitonin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1986)
Primary target: yes
Median affinity:  pEC50
Reference (Journal): Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes.
Published in: Mol Pharmacol

Ligand: calcitonin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1986)
Primary target: yes
Median affinity:  pEC50
Reference (Journal): An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or -3.
Published in: Endocrinology

Ligand: calcitonin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1986)
Primary target: yes
Median affinity:  pEC50
Reference (Journal): Receptor-activity-modifying protein 1 forms heterodimers with two G-protein-coupled receptors to define ligand recognition.
Published in: Biochem J

Ligand: calcitonin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1986)
Primary target: yes
Median affinity:  pEC50
Reference (Journal): Molecular cloning and functional expression of a third isoform of the human calcitonin receptor and partial characterization of the calcitonin receptor gene.
Published in: Endocrinology

Ligand: calcitonin (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1986)
Primary target: yes
Median affinity:  pEC50
Reference (Journal): Novel calcitonin-(8-32)-sensitive adrenomedullin receptors derived from co-expression of calcitonin receptor with receptor activity-modifying proteins.
Published in: Biochem Biophys Res Commun

Ligand: calcitonin (salmon) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1978)
Primary target: yes
Median affinity:  pEC50
Reference (Journal): Molecular cloning and functional expression of a third isoform of the human calcitonin receptor and partial characterization of the calcitonin receptor gene.
Published in: Endocrinology

Ligand: calcitonin (salmon) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1978)
Primary target: yes
Median affinity:  pEC50
Reference (Journal): Expression of two human skeletal calcitonin receptor isoforms cloned from a giant cell tumor of bone. The first intracellular domain modulates ligand binding and signal transduction.
Published in: J Clin Invest

Ligand: calcitonin (salmon) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1978)
Primary target: yes
Median affinity:  pEC50
Reference (Journal): Iodocalcitonin binds to human calcitonin receptors with higher affinity than calcitonin.
Published in: Endocrinology

Ligand: calcitonin (salmon) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1978)
Primary target: yes
Median affinity:  pEC50
Reference (Journal): Spatial proximity between a photolabile residue in position 19 of salmon calcitonin and the amino terminus of the human calcitonin receptor.
Published in: J Biol Chem

Ligand: CT-(8-32) (salmon) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.199999809265137 pKB
Reference (Journal): Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes.
Published in: Mol Pharmacol

Ligand: CT-(8-32) (salmon) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8.17 pKi
Reference (Journal): Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes.
Published in: Mol Pharmacol

Ligand: davalintide (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 8.279999732971191 pEC50
Reference (Journal): KBP-088, a novel DACRA with prolonged receptor activation, is superior to davalintide in terms of efficacy on body weight.
Published in: Am J Physiol Endocrinol Metab

Ligand: KBP-066 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): The Dual Amylin and Calcitonin Receptor Agonist, KBP-066, Induces an Equally Potent Weight Loss Across a Broad Dose Range While Higher Doses May Further Improve Insulin Action.
Published in: J Pharmacol Exp Ther

Ligand: KBP-088 (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 8.350000381469727 pEC50
Reference (Journal): KBP-088, a novel DACRA with prolonged receptor activation, is superior to davalintide in terms of efficacy on body weight.
Published in: Am J Physiol Endocrinol Metab

Ligand: pramlintide (Peptide)
Interaction type: Agonist
Action: Agonist
Ligand approved: yes
Approval source: FDA (2005)
Primary target: no
Median affinity: 8.260000228881836 pEC50
Reference (Journal): Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors.
Published in: Endocrinology

Ligand: [125I]CT (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKd

Ligand: [125I]CT (salmon) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 10 pKd